Cargando…
A comparability study of 5 commercial KRAS tests
BACKGROUND: Activating mutations in the KRAS gene occur frequently in human tumors, including colorectal carcinomas; most mutations occur in codons 12 and 13. Mutations in KRAS have been associated with poor response to anti-epidermal growth factor receptor antibodies. Therefore, an accurate and rea...
Autores principales: | Oliner, Kelly, Juan, Todd, Suggs, Sid, Wolf, Michael, Sarosi, Ildiko, Freeman, Daniel J, Gyuris, Tibor, Baron, Will, Bakker, Andreas, Parker, Alex, Patterson, Scott D |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2879238/ https://www.ncbi.nlm.nih.gov/pubmed/20398393 http://dx.doi.org/10.1186/1746-1596-5-23 |
Ejemplares similares
-
Reliability of KRAS mutation testing in metastatic colorectal cancer patients across five laboratories
por: Feigelson, Heather Spencer, et al.
Publicado: (2012) -
Short report: Performance evaluation of the Idylla™ KRAS and EGFR mutation tests on paraffin-embedded cytological NSCLC samples
por: Offerman, Saskia, et al.
Publicado: (2021) -
Comparison of two commercial tests (Immy vs. Dynamiker) for cryptococcal capsular antigen
por: Noguera, María Clara, et al.
Publicado: (2021) -
Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer
por: Jänne, P A, et al.
Publicado: (2015) -
Association between KRAS mutation and lung metastasis in advanced colorectal cancer
por: Pereira, A A L, et al.
Publicado: (2015)